Acurx’s DNA pol IIIC Inhibitors Achieve MRSA Reduction and Preserve Gut Diversity
ACXP•Acurx Pharmaceuticals’ DNA pol IIIC inhibitors maintained Bacteroidota-dominant gut communities and prevented Proteobacteria expansion while achieving therapeutic plasma levels and reducing MRSA tissue burden in neutropenic mice. Preclinical candidates are FDA QIDP and Fast-Track eligible and target CDC Serious Threat Gram-positive infections.
1. Preclinical Efficacy and Microbiome Preservation
Acurx Pharmaceuticals presented data showing oral administration of its DNA pol IIIC inhibitors in neutropenic CD-1 mice infected with MRSA achieved therapeutic plasma levels, reduced bacterial load in tissue and preserved gut microbial diversity and Bacteroidota-dominant community structure versus linezolid.
2. Regulatory Advantages and Pipeline Targets
These preclinical candidates are designated FDA QIDP and Fast-Track eligible and are designed to treat Serious Threat Gram-positive infections prioritized by the CDC, including MRSA, VRE and C. difficile, potentially accelerating development timelines.
3. Future Research and Development Plans
A research grant from the Dutch government to Leiden University Medical Center will fund structure-activity studies to optimize pol IIIC inhibitors, supporting advancement of lead compounds for acute bacterial skin infections, pneumonia and post-exposure anthrax prophylaxis.
